Evaluation of the FDA’s Proposed Analytical Testing Methods for Asbestos in Talc-Containing Cosmetic Products
THE MICROSCOPE
2026, Volume 72:2, pp. 75–79
DOI
https://doi.org/10.59082/XZMM4522
AUTHOR
Shu-Chun Su and Mathew Sanchez
ABSTRACT
The U.S. Food and Drug Administration (FDA) has proposed standardized analytical testing methods for detecting and identifying asbestos in talc-containing cosmetic products. This perspective critically examines the scientific, technical, and regulatory implications of the proposed rule, with a focus on ensuring the accuracy, reproducibility, and legal defensibility of asbestos testing. Drawing on more than three decades of experience in forensic asbestos analysis, the authors evaluate five key areas of the FDA proposal: (1) mineral phase identification of the six regulated serpentine and amphibole asbestos species; (2) confirmation of asbestiform habit; (3) definitive identification using indexable zone-axis selected-area electron diffraction (SAED) patterns; (4) attainment of a 95% probability of successful detection at meaningful concentration levels; and (5) implementation of quantitative rather than qualitative polarized light microscopy (PLM) methods. This analysis highlights methodological gaps, proposes refinements based on established EPA, ASTM, and NVLAP-accredited laboratory protocols, and underscores the importance of integrating morphology, elemental composition, and crystal structure criteria in transmission electron microscopy (TEM) asbestos identification. Adoption of these refinements will strengthen the scientific rigor of asbestos analytical testing, safeguard public health, and enhance regulatory compliance in the cosmetics industry.
The FDA has proposed a rule to standardize analytical testing methods for detecting and identifying asbestos in talc-containing cosmetic products, aiming to mitigate public health risks associated with asbestos contamination. Published in the Federal Register on December 27, 2024 (Docket No. FDA-2023-N-4225), this proposal mandates the use of PLM and TEM with energy-dispersive spectroscopy EDS and SAED. This perspective evaluates the FDA’s approach across four critical areas, offering refinements to enhance its scientific rigor and practical utility for mineralogical analysis.
Only complete issues for this publication year are available for $25 each, plus shipping; individual articles are not for sale. To request a complete issue, or for any other inquires, please send email to themicroscope@mcri.org.
Shipping: Unless you specify otherwise, the shipping will be 3-5 day Priority Mail through the United States Postal Service.